logo
Paying the price for our toxin addiction

Paying the price for our toxin addiction

'How badly are we messing up? Badly. Can we stop? It's hard: we're addicted to our own toxins. What are the penalties for not stopping? Severe.' So said Margaret Atwood, reflecting on our toxic chemical habits.
By mid-summer, the scent of soil is joined by something far more troubling: chemical traces from weed killers, pesticides and other toxins saturating farms, parks and gardens. This raises urgent questions: why are these substances still so widespread, and who is paying the price? The short answer: private sector interests continue to drive chemical use, often at the cost of human and ecological health.
From soil to system
The impact of these toxic chemicals is made clear in numerous reports documenting dramatic declines in insect populations, as well as the birds and other animals that feed upon them. A recent study of US imperilled species found that while land and sea use change and climate change were the most prevalent threats, pollution was the fourth-most important factor and most species were threatened by a combination of several factors.
The combination of toxic pollution, climate change and biodiversity loss (' triple planetary crisis ') has put human health and well-being in danger. Scientists have documented that the Earth is now beyond the safe operating limit to support humanity with six out of nine planetary boundaries exceeded, one of which is 'novel entities' such as pesticides and other toxic chemicals.
The commercial determinants of health
Business, market and political practices, favourable policy environments and global drivers such as market-driven economies and globalization have contributed to the ill health and injustices associated with hazardous chemicals.
Why are pesticides still so widespread, and who is paying the price? write Jane McArthur, Raquel Feroe and Trevor Hancock
A greater understanding of the impact of private sector activity on human health originated in the 2010s with the concept of commercial determinants of health. This field, situated within public health, recognizes that commercial strategies, shaped by both political and economic systems, can significantly influence health outcomes, social inequality, climate change and pollution, positively and negatively.
The concept of commercial determinants of health shows how corporate strategies — enabled by political and economic systems — can shape health, inequality, climate change and pollution, both positively and negatively.
Indigenous peoples and children are particularly affected
Indigenous Peoples are directly impacted by pesticide use. For example, glyphosate and other herbicides are widely used in forestry, which disrupts traditional Indigenous harvesting and violates harvesting rights. As such, Indigenous communities have advocated for action by governments on pesticide spraying, but little action has been taken.
The federal government's own survey data reveals that Indigenous Peoples in Canada have less confidence that Health Canada is doing a good job of protecting human health and the environment from pesticides, compared with non-Indigenous people in Canada. Indigenous knowledgekeepers and land stewards have asserted that ' pesticides have no place in Indigenous stewardship.' This begs the question to what extent, if any, is there a place for pesticides given the current triple planetary crisis?
Unions, such as the United Food and Commercial Workers, have expressed their concern about pesticide overuse, especially as it impacts workers in the agricultural and food processing sectors, who face health consequences. Overuse of dangerous pesticides is linked to a growing reliance on vulnerable labour such as migrant workers, a move that has been criticized by UN Special Rapporteurs.
Pesticide exposure is especially harmful to children due to biological and developmental factors. As well, children may face greater exposure to pesticide residue found indoors due to behavioral factors (crawling, mouthing etc.). Adverse health impacts for children exposed to pesticides include altered behaviour, liver cancer, brain tumours, endocrine system impacts and effects on puberty. In light of those concerns, the widespread use of pesticides in the home and garden to kill dandelions or ants is a frivolous and unnecessary practice.
Canada can take concrete steps and reverse the status quo
As the host country, Canada played a leadership role in negotiating the Global Biodiversity Framework, aiming to halt and reverse biodiversity loss to sustain life on Earth. Under the Framework, Canada agreed in Target 7 to reduce overall risk from pesticides and highly hazardous chemicals by at least half by 2030. However, Canada currently lacks the infrastructure to systematically manage the growing number of chemical products approved for use.
To meet its commitments under the Framework, Canada must move beyond pledges and take concrete regulatory and policy action.
Health Canada should invest in data collection, safer alternatives, and incentives for industry innovation, while swiftly removing hazardous products containing PFAS, genotoxins, neurotoxins and endocrine disruptors.
The Pesticide Management Regulatory Agency (PMRA) should raise registration fees, and the federal government must enforce the polluter-pay principle so the costs to public health of our chemical addictions can be mitigated.
For the children who play in the dirt, the workers who farm the soil, and the Indigenous communities who maintain a life-giving connection with the land — as well as the rest of us — reducing the development, registration, sale and use of pesticides and other toxic chemicals is necessary. World leaders are not ignorant of this fact.
Jane McArthur is toxics program director at the Canadian Association of Physicians for the Environment (CAPE).
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Public advisory - Risk of anaphylactic reaction associated with glatiramer acetate, used to treat multiple sclerosis Français
Public advisory - Risk of anaphylactic reaction associated with glatiramer acetate, used to treat multiple sclerosis Français

Cision Canada

time4 hours ago

  • Cision Canada

Public advisory - Risk of anaphylactic reaction associated with glatiramer acetate, used to treat multiple sclerosis Français

, /CNW/ - Summary Product: Glatiramer acetate Issue: Health products – Product safety, new safety information What to do: If you experience anaphylactic reaction symptoms, stop taking glatiramer acetate and seek immediate medical help by calling 9-1-1. Report any health product-related side effects to Health Canada. Do not restart taking glatiramer acetate unless your healthcare provider has identified another clear cause for the anaphylaxis. Affected products Issue Health Canada is warning patients that they may experience anaphylactic reactions after receiving glatiramer acetate, which is used to treat relapsing-remitting multiple sclerosis. These anaphylactic reactions can be fatal and may occur at any point during treatment, from as soon as the first dose to months or even years after starting therapy. Anaphylactic reaction symptoms generally appear within one hour of injection and may include: Sudden shortness of breath, wheezing, or difficulty breathing Swelling of the eyelids, face, lips, mouth, tongue, or throat Uncontrolled shaking Fainting or dizziness Trouble swallowing or speaking Widespread rash, hives Collapse Health Canada confirmed this new safety risk following a review of all available data, including 11 Canadian cases of anaphylactic reactions from Copaxone and three additional cases from other glatiramer acetate products. While there have been no fatal cases reported in Canada, some cases required treatment with epinephrine and other appropriate medical interventions. There have been fatal cases reported internationally. Health Canada has informed healthcare professionals, including neurologists, emergency room physicians and staff, nurses, and pharmacists about this new safety risk. The manufacturer for Copaxone has updated its Canadian product labelling to include this risk, and Health Canada is working with the manufacturers of other glatiramer acetate products — including Glatect and Mylan glatiramer acetate injection — to update their respective labelling. What you should do If you experience anaphylactic reaction symptoms, stop taking glatiramer acetate and seek immediate medical help by calling 9-1-1. Do not restart taking glatiramer acetate if you have experienced anaphylaxis unless your healthcare provider has identified another clear cause for the anaphylaxis. Report any health product-related side effects to Health Canada. What healthcare professionals should do Inform patients and/or caregivers of the signs and symptoms of anaphylactic reactions, which may overlap with those of an immediate post-injection reaction. Instruct patients to seek immediate emergency medical care in the event of an anaphylactic reaction. Instruct patients to discontinue treatment with glatiramer acetate if they have an anaphylactic reaction. Do not restart the medicine unless there is another clear reason the patient experienced an anaphylactic reaction. Également disponible en français

Shoppers Foundation for Women's Health commits $1.75M to support further advances in women's health equity Français
Shoppers Foundation for Women's Health commits $1.75M to support further advances in women's health equity Français

Cision Canada

time9 hours ago

  • Cision Canada

Shoppers Foundation for Women's Health commits $1.75M to support further advances in women's health equity Français

TORONTO, Aug. 21, 2025 /CNW/ - There's a crisis in women's health: only 7 per cent of national funding 1 is allocated to women's health research yet 70 per cent of patients with "medically unexplained symptoms 2" are women. The disparity in research funding and increased burden of disease for women is leading to a lack of access to high quality care – and putting women's lives at risk. Shoppers Foundation for Women's Health ™ is pleased to announce that it has invested $1.75 million through its Community Grants Program to help improve the state of women's healthcare across Canada. The work of the 27 organizations receiving grants valued up to a maximum of $100,000 this year spans the women's health landscape addressing areas including improving access to health supports for women experiencing homelessness, gender-based violence, and those in remote or rural communities, as well as initiatives focused on maternal health, menstrual equity, and mental health. "The funding delivered across Canada through our Community Grants program supports vital local charitable programs, awareness initiatives and improved access to care for women," said Paulette Minard, Director of Community Investment at Shoppers Foundation for Women's Health. "Working together with these grant recipients, Shoppers Foundation for Women's Health is committed to making care more equitable and accessible so that all women in Canada can lead healthier lives." Since 2022, the Foundation has supported 99 community-led organizations including The BC Society of Transition Houses (BCSTH) through its Community Grants Program. BCSTH supports an extensive network of member organizations that represent anti-violence workers throughout British Columbia who provide services in women's transitional housing, safe homes and PEACE counselling programs for children and youth. With a donation of $100,000 from Shoppers Foundation for Women's Health, BCSTH was able to address menstrual education and equity as well as increase support through its BCSTH Menstrual Equity Project. "We are proud to partner with Shoppers Foundation for Women's Health to address critical gaps in women's healthcare," said Amy S. FitzGerald, Executive Director at the BC Society of Transition Houses. "Violence impacts not only women's safety and health, but also creates significant financial barriers to equality and well-being. With this grant, we were able to provide menstrual products to nearly 5,000 women, many in rural, remote, and Indigenous communities. This initiative has helped ease some of the burdens faced by women and girls living with violence, and we are deeply appreciative of the continued support from Shoppers Foundation for Women's Health." The full list of recipients of this year's Community Grants program include: Access to Care Christie Refugee Welcome Centre Inc. – Toronto, ON – (Refugee Women's Wellness Program) - $14,800 Malvern Family Resource Centre – Scarborough, ON – (SHE (Support for Health & Equity) Thrives: Expanding Women's Wellness in Malvern) - $19,900 Parkdale Food Centre – Ottawa, ON – (Bridge and Bloom: Supporting Primary Care Access for Women in Ottawa) - $40,000 Alberta Northwest Palliative Care Society – Grande Prairie, AB – (Strengthening the Volunteer Program for Women: Compassion is Contagious) - $50,000 St. John's Women's Centre – St. John's, NL – (Access to Wellness Equity Project -AWEP) - $75,000 GlobalMedic – Toronto, ON – (Mobile Access to Care Program) - $75,000 Ann Davis Transition Society – Chilliwack, BC – (ADTS Mobile Outreach & Connections Project) - $98,746 Sistering-A Woman's Place – Toronto, ON – (Breaking Barriers: Equitable Healthcare for Women and Gender-Diverse People) - $99,475 Street Health Community Nursing Foundation – Toronto, ON – (Pathway to Health & Wellness Women's Drop-In) - $100,000 Vancouver Women's Health Collective Society – Vancouver, BC – (Vancouver Women's Health Collective: Expanding Capacity, and Inclusive Care in the DTES) - $100,000 S.O.S. Grossesse – Quebec City, QC – (Centre de Santé des Femmes de la Capitale-Nationale) - $100,000 Le Reflet (formerly Vide ta sacoche) – Quebec City, QC – (Mieux-être, estime et dignité pour les femmes en situation de vulnérabilité) – $100,000 Gender-Based Violence True North Society – Strathmore, AB – (Advancing Women's Equality) - $20,000 Stepping Stones Crisis Society – Cold Lake, AB – (Circle of Care: Nutrition, Connection, and Wellness for Women) - $33,500 North Shore Crisis Services Society – North Vancouver, BC – (The Welcome Program) - $35,000 Campbell River and North Island Transition Society – Campbell River, BC – (Women's Empowerment Through Better Health Program) - $58,874 Maternal Health First Steps Housing Project – Saint John, NB – (First Steps Residency Program) - $61,790 Shifra Homes Inc. – Burlington, ON – (Health Supports for Homeless Pregnant Women at Shifra Homes) - $75,000 Cape Breton Regional Hospital Foundation – Sydney, NS – (Family Newborn TLC Fund) - $80,000 The Black Women's Institute for Health – Toronto, ON – (Mothering Minds: Motherhood & Mental Health Support) - $100,000 London Health Sciences Foundation – London, ON – (Shoppers Foundation Women's Care Cupboard) - $100,000 Strongest Families Institute / L'institut des Familles Solides – Bedford, NS – (Strongest Beginnings: Equitable Perinatal Mental Health Support Without Barriers) - $100,000 Menstrual Equity Partageons l'espoir (Québec) – Montreal, QC – (FREE feminine hygiene products for all women at our food bank Initiative) - $13,380 United Way of Central Alberta Society – Red Deer, AB – (Period Promise in Central Alberta) – $20,000 Projets autochtones du Québec – Montreal, QC – (Atakaritétshera - Pour la santé et la sécurité des femmes autochtones) - $20,520 L'institut de l'innovation / Innovation Institute – Montreal, QC – (The Refugee Centre Hygiene Basket Initiative) - $60,000 BC Society of Transition Houses – Vancouver, BC – (BCSTH Menstrual Equity Project) - $100,000 Shoppers Foundation for Women's Health is a registered charity. For more information on the Foundation, please visit: About Shoppers Drug Mart Inc. Shoppers Drug Mart Inc. is one of the most recognized and trusted names in Canadian retailing. The company is the licensor of full-service retail drug stores operating under the name Shoppers Drug Mart ® (Pharmaprix ® in Québec). With more than 1,350 Shoppers Drug Mart ® and Pharmaprix ® stores operating in prime locations in each province and two territories, the company is one of the most convenient retailers in Canada. Shoppers Drug Mart ® is an independent operating division of Loblaw Companies Limited. About Shoppers Foundation for Women's Health Shoppers Foundation for Women's Health – the charitable arm of Shoppers Drug Mart ® – is committed to helping Canadian women lead healthier lives, by making care more equitable and accessible. The Foundation will invest $50M by 2026 to address some of the most pressing health inequities facing women, including lack of representation in health research, barriers to accessing mental healthcare, and the urgent consequences women disproportionately face due to poverty and domestic violence. Learn more at

Health Canada grants marketing authorization for an additional indication of Bayer's NUBEQA® (darolutamide) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) Français
Health Canada grants marketing authorization for an additional indication of Bayer's NUBEQA® (darolutamide) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) Français

Cision Canada

time9 hours ago

  • Cision Canada

Health Canada grants marketing authorization for an additional indication of Bayer's NUBEQA® (darolutamide) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) Français

Today's marketing authorization is based on recent results from the Phase III ARANOTE trial and broadens the indication profile of darolutamide in metastatic hormone-sensitive prostate cancer (mCSPC), enabling its use in combination with ADT, with or without chemotherapy (docetaxel) MISSISSAUGA, ON, Aug. 21, 2025 /CNW/ - Bayer Inc. is pleased to announce that Health Canada has granted marketing authorization for its oral androgen receptor inhibitor (ARi) NUBEQA ® (darolutamide) 1 for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). This marketing authorization is based on results from the pivotal 2 Phase III ARANOTE trial, which showed that darolutamide plus ADT reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001) in patients with mCSPC. With this additional marketing authorization, darolutamide plus ADT is the first and only ARi indicated in Canada for the treatment of adult patients with mCSPC, either with or without docetaxel. In addition, darolutamide is approved for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. "This latest authorization reaffirms NUBEQA's role as a therapy for men with prostate cancer," said Shurjeel Choudhri, Senior Vice President and Head of Medical and Scientific Affairs for Bayer Canada. "We extend our thanks to the scientists, doctors, patients, and their families for their contributions that allowed us to offer this new treatment option for metastatic castration-sensitive prostate cancer." "Clinical data from the ARANOTE trial showed that darolutamide is both efficacious and well tolerated as a combination therapy with androgen-deprivation therapy," said Fred Saad, M.D., Professor and Chairman of Surgery and Director of Genitourinary Oncology at the University of Montreal Hospital Center (CHUM), and Principal Investigator of the ARANOTE trial. "Today's approval further expands options for how physicians can use Nubeqa in the treatment of mCSPC, giving them greater flexibility in choosing treatment plans for their patients." In Canada, prostate cancer is the most commonly diagnosed cancer among men, with an incidence rate of 119.7 cases per 100,000 men annually. 3 Among those who are diagnosed, there is a portion of patients who will present with metastatic castration-sensitive prostate cancer (mCSPC), which may occur either de novo (newly diagnosed with metastatic disease) or as metachronous (recurrent disease following treatment for localized prostate cancer). In Canada, approximately 8.6% of all new prostate cancer cases are diagnosed as de novo mCSPC. 4 Prognosis varies by disease stage, and while overall survival for prostate cancer is high, the 5-year net survival rate for patients with stage IV metastatic prostate cancer is approximately 41%, highlighting the need for optimized treatment strategies in this population. ² "Prostate cancer continues to have a significant impact on men and their families in Canada, with incidence and mortality rates that remain unacceptably high," said Dr. Stuart Edmonds, Executive Vice President for Mission, Research and Advocacy at the Canadian Cancer Society. "Bringing more treatments to patients faster offers new hope, greater choice, and the potential for improved outcomes." Darolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company. About the ARANOTE Trial The ARANOTE trial is a randomized, double-blind, placebo-controlled Phase III study designed to assess the efficacy and safety of darolutamide plus ADT in patients with mCSPC. 669 patients were randomized 2:1 to receive 600 mg of darolutamide twice daily or matching placebo in addition to ADT. The primary endpoint of this study is rPFS (radiographic progression-free survival), measured as time from randomization to date of first documented radiological progressive disease or death due to any cause, whichever occurs first. Secondary endpoints include overall survival (time to death from any cause), time to metastatic castration-resistant prostate cancer, time to initiation of subsequent systemic anti-cancer therapy, time to prostate-specific antigen (PSA) progression, PSA undetectable rates, time to pain progression, and safety assessments. Results from the Phase III ARANOTE trial were presented at ESMO 2024 and published in The Journal of Clinical Oncology. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people, and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to Journal of Clinical Oncology: Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics 2023. Toronto, Ontario: Canadian Cancer Society; 2023. Canadian Cancer Society. Survival statistics for prostate cancer. 2021; Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. ___________________ SOURCE Bayer Inc.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store